<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643617</url>
  </required_header>
  <id_info>
    <org_study_id>ACCP002.2</org_study_id>
    <nct_id>NCT00643617</nct_id>
  </id_info>
  <brief_title>CyberKnife Radiosurgery For Low &amp; Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry</brief_title>
  <official_title>Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accuray Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accuray Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of CyberKnife radiosurgery in
      patients with early stage organ-confined prostate cancer and to evaluate the effects of this
      treatment on the quality of life over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, CyberKnife radiosurgery will be used to produce dose distributions comparable
      to those created by HDR brachytherapy treatment, without the use of invasive catheters. The
      radiosurgery volumes will closely be made to resemble HDR brachytherapy therapeutic volumes
      with similar dose limitation objectives to adjacent normal tissues.

      The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of
      treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The
      CyberKnife System delivers radiation using a precise targeting methodology allowing a focal
      treatment margin around the target, thus limiting the volume of adjacent tissue receiving
      high doses radiation. This in turn allows the delivery of high doses of radiation to the
      prostate over a short series of treatments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine biochemical disease free survival (using both ASTRO and Phoenix definitions) and measure the rates of acute and late genitourinary and gastrointestinal toxicities following CyberKnife radiosurgery.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the CyberKnife biochemical disease free survival rates (bDFS) to published HDR monotherapy bDFS rates reported in the literature.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the rates of local failure, distant failure, clinical-disease free survival, disease-specific survival, overall survival and quality of life.</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostate Neoplasms</condition>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>Heterogeneous dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Stereotactic Radiosurgery</intervention_name>
    <description>38 Gy delivered in 4 fractions of 9.5 Gy per fraction</description>
    <arm_group_label>Heterogeneous dose</arm_group_label>
    <other_name>CyberKnife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years of age

          -  Histologically proven prostate adenocarcinoma

          -  Biopsy within 1 year of date of registration

          -  Clinical Stage T1b-T2b, N0, M0

          -  Patients belonging to one of the following risk categories:

          -  Low Risk: CS T1b-T2a, Gleason Score 2-6, PSA &lt; or = 10 ng/ml

          -  Intermediate Risk: CS T2b, Gleason Score 2-6, PSA &lt; or = 10 ng/ml or CS T1b-T2b,
             Gleason Score 2-6, PSA &lt; or = 20 ng/ml or CS T1b-T2b, Gleason Score 7 and PSA &lt; or =
             10 ng/ml

          -  ECOG performance status 0-1

        Exclusion Criteria:

          -  Clinical Stage T2c or greater

          -  Prior prostatectomy or cryotherapy of the prostate

          -  Prior radiotherapy fo the prostate or lower pelvis

          -  Implanted hardware or other material that would prohibit appropriate treatment
             planning or delivery

          -  History of an invasive malignancy other than basal or squamous skin cancers in the
             last 5 years

          -  Hormone ablation for two months prior to enrollment or during treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B Fuller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CyberKnife Centers at San Diego, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Mardirossian, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CyberKnife Centers of San Diego, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mitchell Cancer Center University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasadena Cyberknife Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CyberKnife Centers of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Cyberknife</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Millenium CyberKnife</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Comprehensive Cancer Center</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Radiation Oncology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elmhurst Memorial Hospital</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benefis Health System - Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AtlantiCare Regional Medical Center</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accuray.com</url>
    <description>Accuray Website</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>Stereotactic Radiosurgery</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Prostate Tumor</keyword>
  <keyword>Prostate Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

